
Chiasma, Inc. CHMA
Country |
|
IPO year |
2015 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
52.2 M |
Market Cap[1] |
$ 238 M |
EBITDA (LTM) |
- |
P/E (LTM) |
- |
P/S (LTM) |
- |
EPS (LTM) |
- |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Agios Pharmaceuticals
AGIO
|
$ 29.7 | -0.64 % | $ 1.72 B | Nasdaq Global Select Market,SPB | ||
|
Pfizer
PFE
|
$ 28.06 | -1.46 % | $ 159 B | NYSE,SPB | ||
|
NuCana plc
NCNA
|
$ 0.82 | -7.71 % | $ 9.21 B | Nasdaq Global Select Market | ||
|
Equillium
EQ
|
$ 1.1 | -9.5 % | $ 63 M | Nasdaq Global Market | ||
|
Black Diamond Therapeutics
BDTX
|
$ 1.43 | -1.04 % | $ 81.3 M | Nasdaq Global Select Market,SPB | ||
|
Abeona Therapeutics
ABEO
|
$ 2.73 | 4.81 % | $ 145 M | Nasdaq Capital Market | ||
|
ACADIA Pharmaceuticals
ACAD
|
$ 18.0 | -1.77 % | $ 3.03 B | Nasdaq Global Select Market,SPB | ||
|
Atossa Therapeutics
ATOS
|
$ 1.8 | -5.26 % | $ 15.5 M | Nasdaq Capital Market | ||
|
Cleveland BioLabs, Inc.
CBLI
|
- | -7.31 % | $ 49 M | Nasdaq Capital Market | ||
|
Pliant Therapeutics
PLRX
|
$ 0.66 | 0.38 % | $ 40.5 M | Nasdaq Global Select Market | ||
|
Five Prime Therapeutics, Inc.
FPRX
|
- | - | $ 1.77 B | Nasdaq Global Select Market | ||
|
ADC Therapeutics SA
ADCT
|
$ 1.33 | -1.48 % | $ 169 M | NYSE | ||
|
Harmony Biosciences Holdings
HRMY
|
$ 33.1 | 0.29 % | $ 1.9 B | Nasdaq Global Select Market | ||
|
Ardelyx
ARDX
|
$ 3.15 | -1.1 % | $ 759 M | Nasdaq Global Market | ||
|
Akebia Therapeutics
AKBA
|
$ 0.41 | 2.22 % | $ 105 M | Nasdaq Global Market | ||
|
Alector
ALEC
|
$ 2.56 | 1.17 % | $ 264 M | Nasdaq Global Select Market,SPB | ||
|
ALX Oncology Holdings
ALXO
|
$ 0.97 | -3.11 % | $ 52 M | Nasdaq Global Select Market,SPB | ||
|
Amneal Pharmaceuticals
AMRX
|
$ 21.81 | 3.27 % | $ 6.83 B | NYSE | ||
|
Arbutus Biopharma Corporation
ABUS
|
$ 4.12 | 1.6 % | $ 789 M | Nasdaq Global Select Market | ||
|
Agenus
AGEN
|
$ 6.39 | 2.82 % | $ 190 M | Nasdaq Capital Market | ||
|
PolyPid Ltd.
PYPD
|
$ 6.52 | -0.31 % | $ 107 M | Nasdaq Global Select Market | ||
|
AbCellera Biologics
ABCL
|
$ 11.0 | -0.32 % | $ 3.29 B | Nasdaq Global Select Market | ||
|
Artelo Biosciences
ARTL
|
$ 1.5 | -10.71 % | $ 284 K | Nasdaq Global Select Market | ||
|
Immatics N.V.
IMTX
|
$ 6.11 | -2.94 % | $ 748 M | Nasdaq Global Select Market | ||
|
Aptevo Therapeutics
APVO
|
$ 0.45 | -3.45 % | $ 142 K | Nasdaq Capital Market | ||
|
Aligos Therapeutics
ALGS
|
$ 1.3 | -4.41 % | $ 12.9 M | Nasdaq Global Select Market | ||
|
Aclaris Therapeutics
ACRS
|
$ 3.48 | 2.81 % | $ 427 M | Nasdaq Global Select Market | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
$ 28.47 | -0.07 % | $ 4.32 B | Nasdaq Global Select Market,SPB | ||
|
Cellectar Biosciences
CLRB
|
$ 0.89 | -3.51 % | $ 2.32 M | Nasdaq Capital Market | ||
|
Larimar Therapeutics
LRMR
|
$ 3.22 | 7.69 % | $ 268 M | Nasdaq Global Market | ||
|
Biofrontera AG
BFRA
|
- | -8.24 % | $ 105 M | Nasdaq Capital Market | ||
|
Pulmatrix
PULM
|
$ 1.34 | -2.19 % | $ 4.89 B | Nasdaq Global Select Market | ||
|
Intellia Therapeutics
NTLA
|
$ 9.68 | -1.07 % | $ 1.05 B | Nasdaq Global Market,SPB | ||
|
Pharming Group N.V.
PHAR
|
$ 12.48 | 3.51 % | $ 8.6 B | Nasdaq Global Select Market | ||
|
Catabasis Pharmaceuticals, Inc.
CATB
|
- | -6.97 % | $ 657 M | Nasdaq Global Market | ||
|
Capricor Therapeutics
CAPR
|
$ 8.04 | -4.4 % | $ 374 M | Nasdaq Capital Market | ||
|
Amphastar Pharmaceuticals
AMPH
|
$ 29.66 | 1.91 % | $ 1.39 B | Nasdaq Global Select Market | ||
|
Dr. Reddy's Laboratories Limited
RDY
|
$ 14.98 | 1.28 % | $ 12.5 B | NYSE | ||
|
China Biologic Products Holdings, Inc.
CBPO
|
- | 1.68 % | $ 4.65 B | Nasdaq Global Select Market | ||
|
Regeneron Pharmaceuticals
REGN
|
$ 945.14 | -1.32 % | $ 98.9 B | Nasdaq Global Select Market,SPB | ||
|
Aquestive Therapeutics
AQST
|
$ 3.78 | 2.16 % | $ 404 M | Nasdaq Global Market | ||
|
Jaguar Health
JAGX
|
$ 0.35 | -8.69 % | $ 816 K | Nasdaq Capital Market | ||
|
Arvinas
ARVN
|
$ 6.77 | -0.73 % | $ 480 M | Nasdaq Global Select Market,SPB | ||
|
Cerus Corporation
CERS
|
$ 1.95 | 2.63 % | $ 372 M | Nasdaq Global Market | ||
|
Beam Therapeutics
BEAM
|
$ 21.03 | 1.82 % | $ 2.08 B | Nasdaq Global Select Market | ||
|
Inhibrx
INBX
|
$ 68.87 | -7.16 % | $ 3.25 B | Nasdaq Global Select Market | ||
|
Royalty Pharma plc
RPRX
|
$ 68.76 | 0.12 % | $ 29.6 B | Nasdaq Global Select Market | ||
|
Entera Bio Ltd.
ENTX
|
$ 3.24 | 8.0 % | $ 150 M | Nasdaq Capital Market | ||
|
Revolution Medicines
RVMD
|
$ 159.7 | -1.84 % | $ 30.4 B | Nasdaq Global Select Market | ||
|
Flexion Therapeutics, Inc.
FLXN
|
- | - | $ 459 M | Nasdaq Global Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.